PharmaCyte Biotech Inc. (PMCB) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, PMCB scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows. The Fundamental Cash Engine scores 5 of 20, reflecting ROIC of -30.2% and an FCF yield of 0%; for an investor, this means the business is currently consuming capital rather than generating it, so any upside depends on external funding or a change in operating trajectory that the source data does not show. Whale/13F Flow scores 10 of 20, indicating some institutional accumulation and options positioning, though the source does not provide holder detail to confirm the size or direction of that activity. Insider Conviction scores 5 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow that the rating characterizes as weak support. Macro Regime Fit scores 8 of 20 with a Beta of 1.0 and sector sensitivity noted, meaning the stock moves in line with the market but without a defensive profile. Forensic Balance Sheet scores 7 of 20, with an Altman Z-Score of 0.2, a Piotroski F-Score of 2 out of 9, and Debt/Equity of 0.5, all of which point to elevated financial distress risk. Taken together, the prospective investor faces a sub-dollar, micro-cap equity with negative returns on capital, zero free cash flow yield, and weak forensic signals. Any upside case rests on catalysts and financing outcomes that the source data does not quantify, while valuation tradeoffs are not measurable here because earnings-based multiples are unavailable.

PharmaCyte Biotech Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Biological Products (No Diagnostic Substances), per the SEC profile. The source data does not identify specific products, customers, or revenue-generating activities. Reported revenue is $0.0M in each listed period, per the SEC financials. Not available in source data for how the company makes money.

Per the SEC financials, revenue is zero across all three periods and operating income is negative in each. Net income swings from $0.3M in FY 2023 to $30.7M in FY 2024 and then to $-19.4M in FY 2025, a pattern the source does not explain. Per the market data, gross, operating, and net margins are all 0%, and ROIC is -30.2%. The Roarable RQD rating reports an Altman Z-Score of 0.2 and a Piotroski F-Score of 2 out of 9, signaling distress and weak fundamentals. The balance sheet shows Debt/Equity of 0.5, while reported debt is N/A in the SEC financials.

Per the recent news feed, six items reference PMCB. Headlines include a TradingView estimates report, a report describing a 5.45% move to $0.36 with AD line divergence, a TradingKey top-losers listing, a Traders Union price prediction piece and a live price page, and an ICICI Bank item that is unrelated to PMCB and mentions it only by feed association. Impact labels are MARKET WIRE and CATALYST; no specific corporate event, filing, or trial readout is described in the source text. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present. Risk watch items are the price proximity to the 52-week low of $0.3, the loss-making financial trend, and the low absolute market capitalization.

• What specific operations or programs generate the company's activity, given zero reported revenue?
• What drove the swing in net income from $0.3M in FY 2023 to $30.7M in FY 2024 and then to $-19.4M in FY 2025?
• What is the reported debt balance, since the SEC financials list debt as N/A while Debt/Equity is 0.5?
• What is the company's cash runway relative to its $-5.2M FY 2025 free cash flow burn?
• What institutional and insider holdings exist, since the holders section is empty?